awmsg logo



liraglutide (Victoza®)


Reference No. 1395

Publication date:
11/03/2015


Appraisal information

liraglutide (Victoza®) 6 mg/ml solution for injection


Company: Novo Nordisk Ltd
BNF category: Endocrine system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 10/03/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, liraglutide (Victoza®) cannot be endorsed for use within NHS Wales for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin, or in combination with basal insulin and oral glucose-lowering medicinal products, when these together with diet and exercise, do not provide adequate glycaemic control
Statement of Advice (SOA)
Download